1. Home
  2. OPT vs PFLT Comparison

OPT vs PFLT Comparison

Compare OPT & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
    SELLHOLDBUYas of 3 days ago
  • PFLT
    SELLHOLDBUYas of 3 days ago
  • Stock Information
  • Founded
  • OPT 1984
  • PFLT 2010
  • Country
  • OPT Australia
  • PFLT United States
  • Employees
  • OPT N/A
  • PFLT N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PFLT Finance: Consumer Services
  • Sector
  • OPT Health Care
  • PFLT Finance
  • Exchange
  • OPT Nasdaq
  • PFLT Nasdaq
  • Market Cap
  • OPT 767.9M
  • PFLT 885.6M
  • IPO Year
  • OPT 2020
  • PFLT N/A
  • Fundamental
  • Price
  • OPT $3.34
  • PFLT $10.70
  • Analyst Decision
  • OPT Strong Buy
  • PFLT Strong Buy
  • Analyst Count
  • OPT 1
  • PFLT 2
  • Target Price
  • OPT $12.00
  • PFLT $12.00
  • AVG Volume (30 Days)
  • OPT 12.3K
  • PFLT 858.2K
  • Earning Date
  • OPT 08-30-2024
  • PFLT 02-05-2025
  • Dividend Yield
  • OPT N/A
  • PFLT 11.52%
  • EPS Growth
  • OPT N/A
  • PFLT 80.92
  • EPS
  • OPT N/A
  • PFLT 1.40
  • Revenue
  • OPT $261,859.00
  • PFLT $186,355,000.00
  • Revenue This Year
  • OPT N/A
  • PFLT $23.81
  • Revenue Next Year
  • OPT $46,864.64
  • PFLT N/A
  • P/E Ratio
  • OPT N/A
  • PFLT $7.64
  • Revenue Growth
  • OPT N/A
  • PFLT 33.74
  • 52 Week Low
  • OPT $1.79
  • PFLT $10.28
  • 52 Week High
  • OPT $5.45
  • PFLT $12.63
  • Technical
  • Relative Strength Index (RSI)
  • OPT 43.16
  • PFLT 31.36
  • Support Level
  • OPT $3.15
  • PFLT $10.67
  • Resistance Level
  • OPT $3.39
  • PFLT $10.97
  • Average True Range (ATR)
  • OPT 0.18
  • PFLT 0.13
  • MACD
  • OPT -0.00
  • PFLT -0.03
  • Stochastic Oscillator
  • OPT 27.49
  • PFLT 21.19

Stock Price Comparison Chart: OPT vs PFLT

OPT
PFLT
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober0246810121416OPT VS PFLT

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

About PFLT PennantPark Floating Rate Capital Ltd.

PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use